Arbutus Biopharma (ABUS) Misses Q3 EPS by 5c

Arbutus Biopharma (NASDAQ: ABUS) reported Q3 EPS of ($0.27), $0.05 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $1.52 million versus the consensus estimate of $1.66 million.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• Dollar Tree upgraded on earnings upside potential despite ongoing traffic woes
• Helen of Troy (HELE) Tops Q1 EPS by 22c, Beats on Revenue; Offers FY Guidance
• Kura Sushi (KRUS) Tops Q3 EPS by 3c; offers outlook